RSS   Newsletter   Contact   Advertise with us

Exact Sciences to acquire Thrive Earlier Detection in deal worth up to $2.15 billion

Christian Fernsby ▼ | October 27, 2020
Exact Sciences said Tuesday it has agreed to acquire Thrive Earlier Detection in a cash and stock deal worth up to $2.15 billion.
Exact Sciences
Thrive Earlier Detection   Exact Sciences
Thrive Earlier is a health care company that aims to bring early cancer detection into routine medical care.

Topics: Exact Sciences Thrive Earlier Detection

The deal is expected to close in the first quarter of 2021.

"Combining Thrive's pioneering early stage screening test, CancerSEEK, with Exact Sciences' best in class scientific platform, clinical organization, and commercial infrastructure will establish Exact Sciences as a leading competitor in blood based, multi cancer screening," the company said in a statement.